关于快食葡萄糖受损的风险因素的研究和基于极端梯度增强算法预测模型的开发
Qiyuan Cui1, Jianhong Pu1, Wei Li2
1Department of Geriatrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Frontiers in endocrinology
|October 9, 2024
概括
使用XGBoost的机器学习模型可以预测老年人的禁食葡萄糖 (IFG) 损失. 关键预测因素包括静脉血压,脂肪肝,腰围和血清肌素,有助于早期识别.
科学领域:
- 老年学和老年医学是老年学和老年医学.
- 生物医学信息学 生物医学信息学
- 心血管健康 心血管健康
背景情况:
- 禁食葡萄糖 (IFG) 障碍是2型糖尿病的前体,对中年和老年人群构成重大健康风险.
- 早期识别面临IFG风险的个体对于及时干预和疾病预防至关重要.
- 预测模型可以提高临床决策和老年护理资源分配.
研究的目的:
- 开发和验证基于机器学习 (ML) 的模型,用于预测禁食葡萄糖 (IFG) 损失的5年发病率.
- 确定与中年和老年人IFG发育相关的关键临床和生化因素.
- 将各种ML算法的性能与IFG预测的传统后勤回归进行比较.
主要方法:
- 一项回顾性队列研究,涉及来自苏州大学第一附属医院的1855名参与者 (2018-2022).
- 使用了极端梯度提升 (XGBoost),支向量机 (SVM),天真湾,决策树 (DT) 和后勤回归 (LR) 模型.
- 采用Boruta算法和物流多变量回归来进行特征选择,使用AUC,校准曲线和DCA评估模型性能.
主要成果:
- XGBoost 模型表现出优异的预测性能,在验证集上,曲线下的面积 (AUC) 为 0.7391.
- 确定IFG发展的重要预测因素包括静脉血压 (SBP),脂肪肝,腰围 (WC) 和血清肌素 (Scr).
- 开发的模型有效地区分了在5年研究期间将进入IFG的个人.
结论:
- 结合SBP,脂肪肝,WC和Scr的XGBoost模型显示,对中年和老年人早期IFG风险识别有前途.
- 这种基于ML的方法可以作为临床医生在主动IFG管理中的宝贵工具.
- 需要在多种不同人群中进行进一步的验证,以确认预测模型的通用性.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
512
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
512
Hypoglycemia and Glucagon
164
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes
881
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
881
Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
Dipeptidyl Peptidase 4 Inhibitors
173
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
173


